A lot of Sunesis investors have emailed me about the recent Effectiveness order by the SEC for their recent S-3 amendment, Effectiveness order was filed yesterday. I have had a lot of questions asking whether or not this filing would spell more dilution for current shareholders. And the answer is NO, and here’s why. » Read more: Sunesis Pharmaceuticals (SNSS) Shelf Filing
Posts Tagged ‘snss’
Sunesis Pharmaceuticals (SNSS) Shelf Filing
September 2nd, 2010Epicept Corporation (EPCT): Victim of FDA Politics? What all Cancer Company Investors Need to Know
August 23rd, 2010Before I start, don’t forget my deal of the day! Today back by popular demand I have the TradeKing deal. Also, don’t forget if you have to make any type of purchase from Amazon simply follow my link here, any purchase will help GekkoWire out and there are no extra charges to you, just a simple click on a link!!!!
Get $50 when you open a TradeKing account today. » Read more: Epicept Corporation (EPCT): Victim of FDA Politics? What all Cancer Company Investors Need to Know
Daily Pharma Watch
August 4th, 2010Sunesis Pharmaceuticals (SNSS):
Zacks Premium FULL ACCESS Membership – 30-day free trial
So investors in Sunesis have finally gotten some word on the progress of the Phase III trial of voreloxin in AML patients. The company said this morning that they have put together a Steering Committee and other partners for the Phase III trial of the drug. The company also noted that the drug will now be called vosaroxin as accepted by the United States Adopted Names Council. » Read more: Daily Pharma Watch
Dr. Pazdur Speaks out on Cancer Trials and Accelerated Approvals
July 29th, 2010Dr. Pazdur Speaks out on Cancer Trials and Accelerated Approvals
So a lot of investors have been wondering what will happen to cancer drugs that are in the Accelerated approval process because of the recent fiasco surrounding Avastin. For those that don’t know the story, Avastin is a drug for breast cancer that has had significant setbacks. The drug was approved under the FDA’s coveted Accelerated Approval Process. » Read more: Dr. Pazdur Speaks out on Cancer Trials and Accelerated Approvals
Cell Therapeutics (CTIC) : Financing Options Ahead
July 27th, 2010So I have gotten a lot of questions about whether or not I think Cell Therapeutics will effect a reverse stock split or if they will need to raise capital. So per my last post back at the beginning of July I briefly went through their financing situation. Here it is: » Read more: Cell Therapeutics (CTIC) : Financing Options Ahead
Sunesis Pharmaceuticals (SNSS): Quick Update
July 23rd, 2010Sunesis Pharmaceuticals (SNSS):
So I have gotten a lot of questions in regards to Sunesis’ upcoming Phase III trial for their lead product Voreloxin and whether or not the company is going to be doing the trial under an SPA. For the record I would like to say that I am indifferent on whether or not a company developing a cancer drug chooses to do so under the SPA process. This is because cancer trials are so common that their endpoints are similar across all trials. Furthermore, an analysis I did of cancer drugs that went in front of an FDA advisory panel in 2009 that either had an SPA or did not have SPA seemed to show that simply having an SPA had no bearing on whether the drug got approved or not. » Read more: Sunesis Pharmaceuticals (SNSS): Quick Update
Daily Pharma Watch
July 15th, 2010Daily Pharma Watch
Today is the big day for Vivus, they will meet with an advisory panel to discuss their lead product Qnexa. I am expecting a decision to come out around 1:30-2:00 pm. The only real thing investors can do now is wait and see what happens, trading in the stock is halted, but should resume after the announcement or tomorrow. » Read more: Daily Pharma Watch
Sunesis Pharmaceuticals (SNSS): Raises Cash Moves Towards Phase III Trial of Voreloxin in AML Patients
July 2nd, 2010Sunesis Pharmaceuticals (SNSS): Raises Cash
Sunesis said late yesterday that they had been able to raise more cash in a deal that was arranged back in 2009. The company said that under the deal they were able to raise a net amount of $28.5 million, which was the remaining tranche of a deal worked out on March 31, 2009 of last year (filing here). » Read more: Sunesis Pharmaceuticals (SNSS): Raises Cash Moves Towards Phase III Trial of Voreloxin in AML Patients
Special Protocol Assessment: The REAL DEAL Analysis: ZIOPHARM Oncology (ZIOP), Keryx Pharmaceuticals (KERX), AEterna Zentaris (AEZS), Delcath Systems (DCTH), Sunesis Pharmaceuticals (SNSS)
June 22nd, 2010Special Protocol Assessment: The REAL DEAL Analysis: ZIOPHARM Oncology (ZIOP), Keryx Pharmaceuticals (KERX), AEterna Zentaris (AEZS), Delcath Systems (DCTH), Sunesis Pharmaceuticals (SNSS)
This post will actually be useful for several cancer companies out there so I have also included their names in the header, sorry for the ridiculously long title.
Alright ZIOPHARM investors, I have been asked what drugs garnered approval without an SPA designation by some readers. Last year, I had put together a post about how the Oncology Advisory Committee had voted in 2009, so I decided to repost that list and then include whether or not the company had received an SPA for the trial. This list focuses on cancer drugs only, so it is directly relevant to ZIOPHARM and other oncology companies with drugs in Phase III trials. » Read more: Special Protocol Assessment: The REAL DEAL Analysis: ZIOPHARM Oncology (ZIOP), Keryx Pharmaceuticals (KERX), AEterna Zentaris (AEZS), Delcath Systems (DCTH), Sunesis Pharmaceuticals (SNSS)
Sunesis Pharmaceuticals (SNSS): Current Share Price and Reverse Stock Split Analysis
June 18th, 2010Sunesis Pharmaceuticals (SNSS) Shares Outstanding
So most long term Sunesis shareholders are aware that the company recently got the go ahead vote for permission to do a Reverse Stock split if needed. On June 8, 2010 the company noted in an Edgars filing (here) that they had received the shareholders go ahead to do reverse split “if” needed in a vote. The day this filing was announced the stock sunk some 15-20% on the news and has yet to recover, it also didn’t help that during the conference call the company didn’t sound as bullish on a partnership as it did in the past. » Read more: Sunesis Pharmaceuticals (SNSS): Current Share Price and Reverse Stock Split Analysis
Twitter
